After reading this note you will be able to recognise, investigate and outline the immediate and definitive management of chronic liver disease and cirrhosis in Kenyan clinical settings. Always verify drug choices, doses and local protocols against the Kenya MoH guideline and your hospital formulary.
Definition
Chronic liver disease (CLD) is a progressive, usually irreversible disorder of hepatic structure and function lasting > 6 months, characterised by fibrosis, architectural distortion and, in advanced stages, cirrhosis.
Cirrhosis is the end‑stage of CLD in which normal hepatic lobules are replaced by regenerative nodules surrounded by fibrous septa, leading to portal hypertension and loss of synthetic, detoxifying and metabolic capacity.
Anatomy and physiology you need
| Structure | Relevance to CLD |
|---|---|
| Hepatocytes | Primary site of metabolism, detoxification, protein synthesis; injury initiates fibrosis |
| Sinusoids | Endothelial barrier; loss → portal hypertension |
| Portal triad (portal vein, hepatic artery, bile duct) | Conduit for inflow; fibrosis narrows vessels → increased portal pressure |
| Central vein | Outflow tract; congestion contributes to hepatic congestion |
| Bile canaliculi | Damage → cholestasis, jaundice |
| Collagen‑producing stellate cells | Activation → extracellular matrix deposition, fibrosis |
| Liver capsule & peritoneum | Stretching → ascites, abdominal discomfort |
Causes and risk factors
| Category | Common aetiologies in Kenya |
|---|---|
| Viral | Chronic hepatitis B (endemic), hepatitis C (especially in people who inject drugs) |
| Alcoholic | Heavy (> 60 g ethanol/day) or chronic consumption of locally brewed spirits |
| Metabolic | Non‑alcoholic fatty liver disease (obesity, diabetes), haemochromatosis (rare) |
| Autoimmune | Autoimmune hepatitis, primary biliary cholangitis |
| Infectious (tropical) | HIV (direct hepatic injury, drug toxicity), disseminated TB, malaria (repeated severe episodes), schistosomiasis (S. mansoni), visceral leishmaniasis |
| Hematologic | Sickle cell disease (repeated vaso‑occlusive hepatic infarcts), thalassaemia |
| Drug‑induced | Traditional herbal remedies, antitubercular therapy (isoniazid, rifampicin), antiretrovirals (especially nevirapine), antimalarials (artemisinin derivatives) |
| Vascular | Budd‑Chiari syndrome (hepatic vein thrombosis), portal vein thrombosis |
| Others | Wilson disease (copper overload), alpha‑1 antitrypsin deficiency |
Pathophysiology
Chronic insult → hepatocyte death → inflammatory cytokines → activation of hepatic stellate cells → collagen deposition → fibrosis → architectural distortion → nodular regeneration → portal hypertension → clinical decompensation.
Short causal steps with arrows
- Persistent viral/ toxic/alcoholic injury → hepatocyte necrosis/apoptosis
- Release of damage‑associated molecular patterns → Kupffer cell activation → TNF‑α, IL‑6, TGF‑β
- TGF‑β drives hepatic stellate cell trans‑differentiation → myofibroblast phenotype
- Myofibroblasts secrete type I & III collagen → extracellular matrix accumulation
- Fibrous septa bridge portal tracts and central veins → loss of sinusoidal perfusion
- Regenerative nodules form around surviving hepatocytes → nodular architecture
- Increased intra‑hepatic vascular resistance → portal hypertension → splenomegaly, varices, ascites
- Decline in synthetic function (albumin, clotting factors) & detoxification → encephalopathy, coagulopathy
Clinical features
| Domain | Key questions / findings | Why it occurs |
|---|---|---|
| History – constitutional | Fatigue, weight loss, anorexia, low‑grade fever, night sweats | Chronic inflammation and impaired hepatic metabolism reduce energy stores; fever may signal active hepatitis or infection (e.g., TB, HIV). |
| History – gastrointestinal | Appetite change, early satiety, nausea, vomiting, abdominal distension, change in stool colour (pale, tarry), pruritus, haematemesis or melena | Early satiety & nausea from enlarged liver (hepatomegaly) or ascites; pale stools from cholestasis; tarry stools from variceal bleed; pruritus from bile salt deposition. |
| History – alcohol / toxin exposure | Quantity and duration of alcohol, use of traditional herbal remedies, acetaminophen, industrial solvents | Direct hepatotoxicity accelerates fibrosis; dose‑response relationship helps gauge contribution. |
| History – viral / infectious | Prior hepatitis B/C testing, HIV status, TB treatment, malaria episodes, schistosomiasis exposure, transfusion history | Chronic viral hepatitis, HIV‑related liver disease, TB drugs (isoniazid, rifampicin) and malaria can cause chronic injury; schistosomiasis leads to periportal fibrosis. |
| History – metabolic / systemic | Diabetes, obesity, dyslipidaemia, hypertension, family history of liver disease, sickle‑cell crises, rheumatic fever, use of steroids or immunosuppressants | Metabolic syndrome drives non‑alcoholic fatty liver disease (NAFLD); sickle‑cell disease causes hepatic infarction; rheumatic disease may involve immune‑mediated hepatitis. |
| History – bleeding / clotting | Easy bruising, epistaxis, gum bleeding, prolonged bleeding after minor cuts | Reduced synthesis of clotting factors (II, VII, IX, X) and thrombocytopenia from splenic sequestration. |
| History – encephalopathy | Confusion, personality change, asterixis, sleep reversal, forgetfulness | Accumulation of ammonia and other neurotoxins due to impaired hepatic detoxification. |
| Examination – general | Jaundice, spider angiomas, palmar erythema, gynecomastia, muscle wasting | Hyperbilirubinaemia → jaundice; estrogen excess from reduced metabolism → spider angiomas, gynecomastia; chronic catabolism → wasting. |
| Examination – abdomen | Hepatomegaly, firm nodular liver edge, splenomegaly, ascites (shifting dullness, fluid wave), caput medusae, umbilical hernia | Fibrotic liver becomes nodular and may enlarge; portal hypertension → splenomegaly, collateral veins (caput medusae), ascites; increased intra‑abdominal pressure predisposes to umbilical hernia. |
| Examination – stigmata of portal hypertension | Dilated abdominal veins, palpable left renal vein, hemorrhoids, rectal varices | Collateral circulation forms to bypass high portal pressure. |
| Examination – neurologic | Asterixis, flapping tremor, altered mental status | Hepatic encephalopathy due to neurotoxin buildup. |
| Examination – skin | Pruritus, xanthomas, bruising, petechiae | Cholestasis → pruritus; hyperlipidaemia in cholestatic disease → xanthomas; coagulopathy → bruising/petechiae. |
Differential diagnosis
| Condition | Points toward it | How to separate |
|---|---|---|
| Alcoholic liver disease | Heavy regular alcohol, AST : ALT > 2, history of binge drinking | AST/ALT ratio, presence of macro‑vesicular steatosis on imaging, lack of viral markers |
| Chronic viral hepatitis (HBV/HCV) | Positive serology, risk factors (IV drug use, transfusion), ALT > AST | Serology, PCR viral load, absence of significant alcohol use |
| Non‑alcoholic fatty liver disease (NAFLD) | Obesity, diabetes, dyslipidaemia, minimal alcohol | Imaging showing steatosis, metabolic risk profile, negative viral/HIV tests |
| Schistosomiasis‑related periportal fibrosis | Rural exposure, freshwater contact, eosinophilia | Stool ova detection, ultrasound showing “pipe‑stem” fibrosis, serology |
| Autoimmune hepatitis | Female, other autoimmune disease, high IgG, ANA/ASMA positive | Autoantibody profile, response to steroids, lack of significant fibrosis on imaging early |
| Drug‑induced liver injury (e.g., isoniazid, antiretrovirals) | Recent TB or HIV therapy, herbal medicine use | Temporal relationship to drug start, improvement on withdrawal |
| Congestive hepatopathy (right‑sided heart failure) | Peripheral oedema, JVP elevation, cardiac history | Echocardiography showing RV dysfunction, pulsatile liver |
| Hemochromatosis | Family history, bronze skin, diabetes, high ferritin | Iron studies (transferrin saturation > 45 %), genetic testing |
| Wilson’s disease | Young adult, neuropsychiatric symptoms, Kayser‑Fleischer rings | Low ceruloplasmin, high urinary copper, slit‑lamp exam |
Investigations
| Test | What it answers | Interpretation |
|---|---|---|
| Liver function panel (ALT, AST, ALP, GGT, bilirubin, albumin, PT/INR) | Hepatocellular injury vs cholestasis, synthetic function | ALT > AST → viral/NAFLD; AST > ALT ×2 → alcohol; ALP/GGT ↑ → cholestasis; low albumin/ prolonged PT → decompensation |
| Full blood count & peripheral smear | Cytopenias, eosinophilia, hemolysis | Thrombocytopenia → splenic sequestration; eosinophilia → parasitic infection |
| Viral serology (HBsAg, anti‑HBc, HCV antibody, HIV) | Chronic infection status | Positive → viral aetiology |
| Autoimmune panel (ANA, ASMA, IgG) | Autoimmune hepatitis | Positive titres + high IgG → AIH |
| Iron studies (serum ferritin, transferrin saturation) | Hemochromatosis | Saturation > 45 % suggests iron overload |
| Ceruloplasmin & 24‑h urinary copper | Wilson’s disease | Low ceruloplasmin, high urinary copper → Wilson’s |
| Abdominal ultrasound with Doppler | Liver size, nodularity, ascites, portal vein flow, splenomegaly | Nodular liver + portal hypertension signs → cirrhosis; Doppler assesses portal pressure |
| Transient elastography (FibroScan) | Stiffness → fibrosis stage | > 12 kPa generally indicates cirrhosis |
| Upper GI endoscopy | Presence of oesophageal/gastric varices | Varices → portal hypertension, need for prophylaxis |
| Ascitic fluid analysis (if ascites) | Rule out infection, calculate SAAG | SAAG > 1.1 g/dL → portal hypertension related |
| Hepatic ultrasound‑guided biopsy (selected) | Definitive histology, grade of activity | Confirms etiology when non‑invasive tests inconclusive |
Diagnosis and severity
Diagnosis is made when chronic liver injury is documented (≥ 6 months) with imaging or histology showing fibrosis/cirrhosis, supported by a compatible clinical picture and exclusion of reversible causes.
Severity assessment combines:
- Child‑Turcotte‑Pugh (CTP) score – uses encephalopathy, ascites, bilirubin, albumin, PT/INR.
- Class A (5‑6 points): compensated, low 1‑year mortality.
- Class B (7‑9 points): partially decompensated, intermediate risk.
- Class C (10‑15 points): decompensated, high short‑term mortality.
- Model for End‑Stage Liver Disease (MELD‑Na) – calculated from bilirubin, creatinine, INR, and sodium; higher values predict higher transplant urgency.
- Complication profile – presence of variceal bleed, refractory ascites, hepatic encephalopathy, or hepatocellular carcinoma upstages urgency for specialist referral or transplant evaluation.
Patients are stratified into compensated (no ascites, encephalopathy, variceal bleed) versus decompensated disease. This guides monitoring frequency, need for prophylactic variceal banding or non‑selective beta‑blockers, and timing of transplant work‑up.
Management
Immediate stabilisation
| Problem | Immediate action | Rationale |
|---|---|---|
| Hemodynamic instability (hypotension, tachycardia) | Give isotonic crystalloid bolus; consider albumin if suspicion of large‑volume ascites with renal dysfunction | Restores intravascular volume, improves renal perfusion |
| Active upper GI bleed | Secure airway if needed, give IV octreotide infusion, start IV proton‑pump inhibitor, transfuse packed red cells to keep Hb ≈ 7‑8 g/dL, request urgent endoscopy | Reduces portal pressure, promotes clot stability, corrects anemia |
| Encephalopathy | Protect airway, give lactulose (or lactitol) orally/NG, consider rifaximin if refractory | Lowers ammonia production and absorption |
| Coagulopathy with bleeding | Give fresh frozen plasma or prothrombin complex concentrate if INR > 2.5 and bleeding; give vitamin K if deficiency suspected | Supplies clotting factors, corrects deficiency |
| Acute kidney injury on cirrhosis | Stop nephrotoxic drugs, give albumin 1 g/kg (max 100 g) over 48 h, monitor urine output, consider early nephrology referral | Improves renal perfusion, prevents hepatorenal syndrome |
Definitive treatment
- Aetiology‑directed therapy – antiviral therapy for hepatitis B/C, alcohol cessation programmes, anti‑TB treatment, antiretroviral optimisation, schistosomiasis praziquantel, sickle‑cell disease disease‑modifying agents.
- Portal hypertension – non‑selective β‑blockers (e.g., propranolol, carvedilol) titrated to reduce resting heart rate to 55‑60 bpm; consider endoscopic variceal ligation for high‑risk varices.
- Ascites – sodium restriction (<2 g/day), diuretics (spironolactone ± furosemide) in a 100:40 ratio, therapeutic paracentesis with albumin replacement for large‑volume removal.
- Hepatic encephalopathy – lactulose titrated to 2–3 soft stools/day; rifaximin added for recurrent episodes.
- Infections – early empirical antibiotics for spontaneous bacterial peritonitis (e.g., third‑generation cephalosporin) pending culture; tailor thereafter.
- Nutritional support – high‑protein (1.2‑1.5 g/kg) diet, supplement with branched‑chain amino acids if needed, vitamin D and zinc.
Monitoring & follow‑up
- Weekly weight, fluid balance, electrolytes, renal function while on diuretics.
- Endoscopy every 1–2 years (or sooner if decompensation) to reassess varices.
- Serum AFP and ultrasound every 6 months for hepatocellular carcinoma surveillance.
- Regular assessment of Child‑Pugh and MELD scores to guide transplant referral.
Contra‑indications & safety
- β‑blockers contraindicated in severe asthma, bradycardia, or decompensated heart failure.
- Lactulose should be stopped if severe diarrhea leads to electrolyte loss.
- Paracentesis without albumin replacement in patients with low serum albumin (<2.5 g/dL) risks circulatory dysfunction.
- NSAIDs and nephrotoxic agents are avoided due to renal vulnerability.
Complications and prognosis
| Complication | Clinical clue | Management principle |
|---|---|---|
| Variceal hemorrhage | Hematemesis, melena, drop in Hb | Endoscopic band ligation ± β‑blocker; consider TIPS if refractory |
| Ascites → spontaneous bacterial peritonitis | Fever, abdominal pain, leukocytosis, ascitic PMN > 250 cells/µL | Empirical cefotaxime/ceftriaxone, albumin infusion |
| Hepatic encephalopathy | Asterixis, altered mental status | Lactulose ± rifaximin, treat precipitating factors |
| Hepatorenal syndrome | Rising creatinine, oliguria, no intrinsic renal disease | Albumin + vasoconstrictor (e.g., terlipressin), early transplant referral |
| Hepatocellular carcinoma | New focal lesion on US/CT, AFP rise | Multidisciplinary oncology review; curative options (resection, ablation, transplant) if early |
| Coagulopathy & bleeding | Prolonged INR, low platelets, mucosal bleeding | Vitamin K, plasma, platelet transfusion as indicated |
| Bone disease (osteoporosis) | Chronic pain, fractures | Calcium, vitamin D, bisphosphonates if indicated |
Prognosis is staged by Child‑Pugh (A‑C) and MELD scores; decompensated cirrhosis (ascites, variceal bleed, encephalopathy) carries a 5‑year survival < 50 % without transplant. Early identification of complications and timely referral improve outcomes.
High‑yield exam points
- Look‑alike conditions: cardiac failure with hepatic congestion, non‑cirrhotic portal hypertension (e.g., schistosomiasis), Budd‑Chiari syndrome.
- Commonest wrong first step: giving diuretics before confirming that ascites is not due to heart failure or nephrotic syndrome.
- Bedside examiner questions:
- “What signs differentiate compensated from decompensated cirrhosis?”
- “Explain why you would avoid NSAIDs in this patient.”
- “How does lactulose improve encephalopathy?”
- “Interpret the Child‑Pugh score you have calculated.”
- “What is the next step after a first variceal bleed?”
Clinical case
Case: A 48‑year‑old male farmer presents with progressive abdominal distension, mild confusion, and a 2‑kg weight gain over 2 weeks. He drinks locally brewed alcohol daily, has a history of treated hepatitis B, and lives in a malaria‑endemic area. Examination reveals spider nevi, palmar erythema, a fluid‑thrill, shifting dullness, asterixis, and a systolic murmur at the right upper sternal border. Labs show bilirubin 3 mg/dL, INR 1.8, albumin 2.8 g/dL, creatinine 1.2 mg/dL, ascitic PMN 180 cells/µL. Ultrasound shows a nodular liver, splenomegaly, and moderate ascites.
Questions
- What is the most appropriate immediate management?
Answer: Stabilise airway, give IV albumin 100 g over 48 h, start lactulose, and arrange urgent diagnostic paracentesis.
- How would you stage the severity of his liver disease?
Answer: Calculate Child‑Pugh (Score = 9 → Class B) and MELD (≈ 12). This indicates decompensated cirrhosis with intermediate prognosis.
- What long‑term therapy should be instituted to reduce his risk of further decompensation?
Answer: Initiate a non‑selective β‑blocker (e.g., propranolol) titrated to target heart rate, enforce strict sodium restriction, and enrol in an alcohol cessation programme.
Practice questions
Question 1
A 55‑year‑old woman with known cirrhosis presents with sudden massive hematemesis. Her blood pressure is 85/50 mmHg, pulse 120 bpm, and she is confused. What is the next best step?
A. Immediate endoscopy
B. IV octreotide and crystalloid bolus
C. Oral propranolol
D. High‑dose vitamin K
Answer: B. IV octreotide and crystalloid bolus
Explanation: Hemodynamic resuscitation and portal pressure reduction precede endoscopy in acute variceal bleed.
Question 2
A patient with ascites has an ascitic fluid analysis showing PMN = 300 cells/µL, culture negative. Which statement is true?
A. No antibiotics are needed; repeat tap in 48 h
B. Start empirical third‑generation cephalosporin and give albumin
C. Give diuretics first to reduce fluid volume
D. Diagnose hepatic encephalopathy
Answer: B. Start empirical third‑generation cephalosporin and give albumin
Explanation: PMN > 250 cells/µL meets criteria for spontaneous bacterial peritonitis; prompt antibiotics and albumin improve survival.
Question 3
Which of the following is a contraindication to starting a non‑selective β‑blocker in a cirrhotic patient?
A. Child‑Pugh A disease
B. Controlled hypertension
C. Severe asthma with frequent attacks
D. Small esophageal varices
Answer: C. Severe asthma with frequent attacks
Explanation: β‑blockers can precipitate bronchospasm; they are avoided in severe reactive airway disease.
Question 4
A 42‑year‑old man with hepatitis C–related cirrhosis has a MELD score of 18. Which intervention is most appropriate?
A. Start interferon monotherapy
B. Refer for liver transplantation evaluation
C. Begin high‑dose diuretics for ascites
D. Schedule routine colonoscopy
Answer: B. Refer for liver transplantation evaluation
Explanation: MELD ≥ 15 indicates transplant consideration; antiviral therapy alone is insufficient at this stage.
Question 5
A cirrhotic patient develops new‑onset jaundice, pruritus, and dark urine. Ultrasound shows a 2 cm hyperechoic lesion in the right liver lobe. What is the next best investigation?
A. Serum AFP measurement
B. Endoscopic retrograde cholangiopancreatography (ERCP)
C. Contrast‑enhanced MRI of liver
D. Liver biopsy under CT guidance
Answer: C. Contrast‑enhanced MRI of liver
Explanation: MRI with liver‑specific contrast is the imaging modality of choice to characterise focal lesions and screen for hepatocellular carcinoma.
Drafted with AI assistance from standard references and reviewed for structure. Check details against your lecture notes and the Kenya MoH guideline.